Activity of quinolones against gram-positive cocci: Mechanisms of drug action and bacterial resistance

被引:46
作者
Schmitz, FJ
Higgins, PG
Mayer, S
Fluit, AC
Dalhoff, A
机构
[1] Univ Klinikum Dusseldorf, Inst Med Microbiol & Virol, D-40225 Dusseldorf, Germany
[2] Univ Utrecht, Eijkman Winkler Inst Med Microbiol, Utrecht, Netherlands
[3] Christian Albrechts Univ Kiel Klinikum, Inst Med Microbiol, Kiel, Germany
关键词
D O I
10.1007/s10096-002-0788-z
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The quinolones are a potent class of antimicrobial agents that target two essential enzymes of bacterial cells: DNA gyrase and topoisomerase IV. Resistance is mediated chiefly through stepwise mutations in the genes that encode these enzymes, leading to alterations of the target site. These mutations occur in an area called the "quinolone resistance determining region". In gram-positive organisms, mutations occur more often in topoisomerase IV than in DNA gyrase. This target preference appears to depend upon two factors: the species of organism and the selecting drug. Resistance can be enhanced by a decrease in intracellular drug concentration, which is mediated through efflux pumps. The newer generation of fluoroquinolones and non-fluorinated quinolones exhibits enhanced activity against gram-positive organisms compared to the older members of this drug class, although development of resistance to these drugs has been demonstrated in vitro. This review gives a chronological perspective of the literature on the action of DNA gyrase and topoisomerase IV and the mechanisms of resistance to quinolones in staphylococci, streptococci and enterococci.
引用
收藏
页码:647 / 659
页数:13
相关论文
共 136 条
  • [1] Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus
    Aeschlimann, JR
    Dresser, LD
    Kaatz, GW
    Rybak, MJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) : 335 - 340
  • [2] Engineering the specificity of antibacterial fluoroquinolones:: Benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase
    Alovero, FL
    Pan, XS
    Morris, JE
    Manzo, RH
    Fisher, LM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) : 320 - 325
  • [3] Topoisomerase IV catalysis and the mechanism of quinolone action
    Anderson, VE
    Gootz, TD
    Osheroff, N
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (28) : 17879 - 17885
  • [4] Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae
    Bast, DJ
    de Azavedo, JCS
    Tam, TY
    Kilburn, L
    Duncan, C
    Mandell, LA
    Davidson, RJ
    Low, DE
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (09) : 2631 - 2634
  • [5] Structure and mechanism of DNA topoisomerase II
    Berger, JM
    Gamblin, SJ
    Harrison, SC
    Wang, JC
    [J]. NATURE, 1996, 379 (6562) : 225 - 232
  • [6] A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus:: Evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux
    Beyer, R
    Pestova, E
    Millichap, JJ
    Stosor, V
    Noskin, GA
    Peterson, LR
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) : 798 - 801
  • [7] Blanksby B.A., 1996, J SWIMMING RES, V11, P40
  • [8] In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus
    Boos, M
    Mayer, S
    Fischer, A
    Köhrer, K
    Scheuring, S
    Heisig, P
    Verhoef, J
    Fluit, AC
    Schmitz, FJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) : 938 - 942
  • [9] Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae
    Brenwald, NP
    Gill, MJ
    Wise, R
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) : 2032 - 2035
  • [10] Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones
    Brisse, S
    Fluit, AC
    Wagner, U
    Heisig, P
    Milatovic, D
    Verhoef, J
    Scheuring, S
    Köhrer, K
    Schmitz, FJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) : 2513 - 2516